CME Group (CME) Rallies 24% YTD: More Room for Upside Left?
Compelling derivative product lines, global presence, a growing proportion of volume from customers outside the United States, focus on over-the-counter clearing services and effective capital deployment continue to drive CME...
Shares of CME Group CME have rallied 23.7% year to date, outperforming the industry’s increase of 22.4% and the Finance sector’s increase of 17.2%. The S&P 500 composite index has risen 22.6% in the said time frame. With a market capitalization of $80.9 billion, the average volume of shares traded in the last three months was 1.3 million.
Image Source: Zacks Investment Research
Compelling derivative product lines, global presence, a growing proportion of volume from customers outside the United States, focus on over-the-counter clearing services and effective capital deployment continue to drive CME Group, which beat earnings estimates in the last four quarters.
Can CME Stock Retain the Momentum?
The Zacks Consensus Estimate for 2022 earnings indicates a year-over-year improvement of 9.3% on 4.4% higher revenues. The expected long-term earnings growth rate is pegged at 5.8%. The consensus estimate has moved nearly 1% north in the past seven days, reflecting analysts’ optimism.
A compelling portfolio driving higher clearing and transaction fees, market data and information services and other revenues should continue to fuel the top line at this Zacks Rank #3 (Hold) company that increased at a six-year CAGR of nearly 8%. Non-transaction related opportunities, over-the-counter offerings and options business should continue to support growth.
This largest futures exchange in the world in terms of trading volume as well as notional value traded boasts a solid market presence with a 90% market share of the global futures trading and clearing services. Increasing electronic trading volume adds scalability and hence leverage to CME Group’s operating model.
A solid liquidity position should continue to support investments in several areas, including organic market data growth and new product extensions and offerings.
CME Group is poised to benefit from increased adoption of a greater number of crypto assets with increased interest across the entire crypto-economy. The launch of Micro Ether futures (MET) earlier this month marked the second micro cryptocurrency product in 2021.
Banking on solid cash flow, CME Group has increased dividends at a five-year CAGR (2017-2021) of 12.5%. The dividend yield is 1.7%, better than the industry average of 0.9%, making the stock an attractive pick for yield-seeking investors.
Stocks to Consider
Some top-ranked stocks include OTC Markets Group OTCM, Cboe Global Markets CBOE and Intercontinental Exchange ICE, each carrying Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for OTC Markets Group’s 2022 earnings has moved up 6.9% in the past 30 days. The expected long-term earnings growth rate is pegged at 9%.
The Zacks Consensus Estimate for Cboe Global’s 2022 earnings indicates a 2.5% year-over-year increase on 3.8% higher revenues. It has an impressive Growth Score of A.
The Zacks Consensus Estimate for Intercontinental’s 2022 earnings has moved up 0.7% in the past seven days and implies a 9.9% year-over-year increase. The expected long-term earnings growth rate is pegged at 10.3%, better than the industry average of 9.5%.
Shares of OTC Markets, Cboe Global and Intercontinental have gained 69.3%, 35.2% and 16.3%, respectively, year to date.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intercontinental Exchange Inc. (ICE): Free Stock Analysis Report
CME Group Inc. (CME): Free Stock Analysis Report
Cboe Global Markets, Inc. (CBOE): Free Stock Analysis Report
OTC Markets Group Inc. (OTCM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research